Note 2 - Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2026

Notes Tables

Segment Reporting [Table Text Block]

	For the Six Months Ended June 30,
	2026									2025
	Cardiac Electrophysiology			Private Aviation			Total			Total
Revenues:
Product revenue
VIVO	$	127		$	—		$	127		$	86
LockeT		391			—			391			269
Total product revenues		518			—			518			355
Service revenue, net
Luxe		—			69			69			—
Hops		—			864			864			—
Total service revenues, net		—			933			933			—
Total revenues		518			933			1,451			355
Less:
Cost of revenues:
Cost of product revenue		53			—			53			25
Cost of service revenue		—			910			910			—
Total cost of revenues		53			910			963			25
Acquired in-process research and development expense		—			—			—			1,967
Depreciation and amortization expense		734			52			786			1,060
Stock-based compensation expense		330			—			330			189
Salaries and benefits expense		1,457			287			1,744			2,624
Professional fees		1,641			163			1,804			1,044
Research and development expense		291			—			291			258
Interest income		(6	)		—			(6	)		(21	)
Interest expense		277			46			323			116
Change in fair value of royalties payable due to related parties		—			—			—			2,830
Change in fair value of trading debt securities		—			—			—			(10	)
Change in fair value of minority equity interest		2,302			—			2,302			—
Change in fair value of deferred consideration		(3,195	)		—			(3,195	)		—
Loss on debt extinguishment		105			—			105			—
Unrealized gains and losses, net		(378	)		—			(378	)		—
Income tax benefit		(487	)		—			(487	)		(1,674	)
Other segment items (1)		1,271			594			1,865			1,450
Segment and consolidated net loss	$	(3,877	)	$	(1,119	)	$	(4,996	)	$	(9,503	)

	For the Three Months Ended June 30,
	2026									2025
	Cardiac Electrophysiology			Private Aviation			Total			Total
Revenues:
Product revenue
VIVO	$	54		$	—		$	54		$	71
LockeT		216			—			216			141
Total product revenues		270			—			270			212
Service revenue, net
Luxe		—			27			27			—
Hops		—			722			722			—
Total service revenues, net		—			749			749			—
Total revenues		270			749			1,019			212
Less:
Cost of revenues:
Cost of product revenue		22			—			22			14
Cost of service revenue		—			899			899			—
Total cost of revenues		22			899			921			14
Acquired in-process research and development expense		—			—			—			1,848
Depreciation and amortization expense		367			15			382			529
Stock-based compensation expense		266			—			266			98
Salaries and benefits expense		647			282			929			1,310
Professional fees		1,127			21			1,148			317
Research and development expense		142			—			142			155
Interest income		(4	)		—			(4	)		(3	)
Interest expense		174			30			204			67
Change in fair value of royalties payable due to related parties		—			—			—			1,667
Change in fair value of trading debt securities		—			—			—			(10	)
Change in fair value of minority equity interest		—			—			—			—
Change in fair value of deferred consideration		(318	)		—			(318	)		—
Loss on debt extinguishment		105			—			105			—
Unrealized gains and losses, net		(378	)		—			(378	)		—
Income tax benefit		(312	)		—			(312	)		(950	)
Other segment items (1)		751			489			1,240			628
Segment and consolidated net loss	$	(2,319	)	$	(987	)	$	(3,306	)	$	(5,458	)

Fair Value, by Balance Sheet Grouping [Table Text Block]

			June 30, 2026
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents
Money market funds	$	12	$	12	$	—	$	—
Marketable securities		1,196		1,196		—		—
Total assets	$	1,208	$	1,208	$	—	$	—
Liabilities:
Royalties payable due to related parties	$	792	$	—	$	—	$	792
Deferred stock issuance liability		647		—		—		647
Total liabilities	$	1,439	$	—	$	—	$	1,439

			December 31, 2025
	Total		Level 1		Level 2		Level 3
Assets:
Cash Equivalents
Money market funds	$	2	$	2	$	—	$	—
Total assets	$	2	$	2	$	—	$	—
Liabilities:
Royalties payable due to related parties	$	792	$	—	$	—	$	792
Convertible notes payable		298		—		—		298
Total liabilities	$	1,090	$	—	$	—	$	1,090

Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Royalties Payable due to Related Parties		Deferred Stock Issuance Liability		Deferred Consideration			Convertible Notes Payable
Balance at January 1, 2026	$	792	$	—	$	—		$	298
Fair value at issuance		—		—		11,028			—
Change in fair value		—		—		(2,877	)		—
Balance at March 31, 2026		792		—		8,151			298
Fair value at issuance		—		601		—			—
Change in fair value		—		46		(318	)		—
Settlement of financial instruments		—		—		(7,833	)		(403	)
Realized (gains) and losses		—		—		—			105
Balance at June 30, 2026	$	792	$	647	$	—		$	—

	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Royalties Payable due to Related Parties		Trading Debt Securities
Balance at January 1, 2025	$	9,213	$	—
Change in fair value		1,163		—
Balance at March 31, 2025		10,376		—
Purchased		—		864
Change in fair value		1,667		10
Balance at June 30, 2025	$	12,043	$	874

Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]

Machinery and equipment	2 - 5 years
Computer hardware and software	1 - 5 years
LockeT animation video	3 years
VIVO DEMO/Clinical Systems	1-5 years

Disaggregation of Revenue [Table Text Block]

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2026		2025		2026		2025
Product Revenue
US	$	210	$	173	$	364	$	308
Europe		60		39		154		47
Total Product Revenue	$	270	$	212	$	518	$	355
Service Revenue
US	$	749	$	—	$	933	$	—
Europe		—		—		—		—
Total Service Revenue	$	749	$	—	$	933	$	—

Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]

	Six Months Ended June 30,
	2026			2025
Deferred revenue, beginning of period	$	—		$	—
Deferred revenue assumed as part of acquisition (see Note 3)		171			—
Revenue recognized during the period related to amounts included in the deferred revenue assumed		(191	)		—
Revenue deferred, net of revenue recognized during the period		165			—
Deferred revenue, end of period	$	145		$	—

Royalties Payable [Member]

Notes Tables

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

Instrument	Valuation Technique	Unobservable Input	Input Range
Royalties payable due to related parties	Discounted future cash flows	Revenue adjusted discount rate		19.5	%
Deferred stock issuance liability	If converted method	Discount for lack of marketability		20	%